Receiving a diagnosis of Parkinson’s disease marks the beginning of a significant life adjustment. The condition is progressive, gradually affecting movement and coordination. For many, the first signs are subtle, a slight tremor in one hand, stiffness that makes buttoning a shirt difficult, or a feeling of slowness when walking. These changes can be frustrating and may spark anxiety about future independence. However, while Parkinson’s is a chronic condition, it is not one that must be faced without defense. 

Treatment plays a pivotal role in maintaining quality of life. The goal is to manage symptoms effectively so individuals can continue working, traveling, and enjoying hobbies for as long as possible. By replenishing or mimicking the brain chemicals responsible for movement, therapy can significantly reduce tremors and improve mobility. Because the disease progresses at different rates for everyone, treatment plans are highly personalized. Doctors adjust medication types and schedules based on the patient’s age, specific symptoms, and lifestyle needs (National Institute on Aging, 2022). 

Overview of treatment options for Parkinson’s Disease 

The primary objective of treating Parkinson’s disease is to restore the balance of dopamine in the brain. Since there is currently no cure to stop the disease from progressing, management focuses on controlling motor symptoms like tremors, rigidity, and bradykinesia (slowness of movement). 

Pharmacological therapy is the cornerstone of management. For most patients, medications are necessary to function daily. In early stages, mild medications may suffice, while advanced stages often require complex drug combinations to maintain steady symptom control. While surgical options like Deep Brain Stimulation (DBS) are standard for patients who no longer respond consistently to medication, drugs remain the primary treatment method. Physical therapy and exercise are also critical companions to medication for maintaining balance and strength. 

Medications used for Parkinson’s Disease 

The most potent and effective medication available is carbidopa-levodopa. Levodopa is a chemical precursor that the brain converts into dopamine. It is almost always combined with carbidopa, which prevents levodopa from breaking down before it reaches the brain. Clinical experience suggests that while this drug offers the best symptom relief, doctors may delay its start in younger patients to manage long-term side effects. 

Dopamine agonists are often used as a first-line treatment for younger patients or added to levodopa later. Drugs like pramipexole and ropinirole do not become dopamine but mimic its effects in the brain. They are generally less effective than levodopa for severe stiffness but have a lower risk of causing involuntary movements initially. 

To prolong the effect of dopamine, doctors may prescribe enzyme inhibitors. MAO-B inhibitors (such as selegiline or rasagiline) and COMT inhibitors (such as entacapone) block the enzymes that naturally break down dopamine. This helps each dose of medication last longer, reducing “off” time where symptoms return before the next pill. 

Anticholinergics, like trihexyphenidyl, are older drugs specifically helpful for reducing tremors in younger patients. Amantadine is another option often used to provide short-term relief for mild symptoms or to control dyskinesia (involuntary movements) in advanced stages (Michael J. Fox Foundation, 2023). 

How these medications work 

Parkinson’s symptoms arise because the brain cells that produce dopamine, a neurotransmitter vital for smooth muscle movement die off. Medications work by compensating for this loss. 

Levodopa crosses the blood-brain barrier, converting to dopamine to restore proper nerve communication. Dopamine agonists directly stimulate receptors, mimicking adequate dopamine levels. Enzyme inhibitors prevent the breakdown of dopamine, maintaining higher levels longer (Mayo Clinic, 2022). 

Side effects and safety considerations 

Parkinson’s medications have significant side effects. Immediate issues include nausea, lightheadedness (especially when standing), and drowsiness. Dopamine agonists risk impulse control disorders (e.g., compulsive gambling, shopping, eating).  

Long-term levodopa use can cause dyskinesia (uncontrolled, jerky movements). Hallucinations or confusion may also occur, particularly in older patients. Never stop Parkinson’s medication abruptly, as this can cause a rare, life-threatening condition called neuroleptic malignant syndrome-like hyperpyrexia. Patients should seek medical help for severe confusion, sudden sleep attacks, or worsening balance. 

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care. 

References 

  1. Mayo Clinic. https://www.mayoclinic.org 
  1. Michael J. Fox Foundation. https://www.michaeljfox.org 
  1. National Institute on Aging. https://www.nia.nih.gov 
  1. Parkinson’s Foundation. https://www.parkinson.org 

Medications for Parkinson's Disease

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Parkinson's Disease.

Found 20 Approved Drugs for Parkinson's Disease

Pramipexole

Generic Name
Pramipexole

Pramipexole

Generic Name
Pramipexole
PRAMIPEXOLE DIHYDROCHLORIDE tablets is a non-ergot dopamine agonist indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease (PD).

Selegiline

Brand Names
EMSAM, Zelapar

Selegiline

Brand Names
EMSAM, Zelapar
Selegiline capsules, USP are indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of 'off' time, and patient self-rating of treatment success. Beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and comparison to previous state).

Ropinirole

Generic Name
Ropinirole

Ropinirole

Generic Name
Ropinirole
Parkinson’s Disease Ropinirole tablets are indicated for the treatment of Parkinson’s disease.

Cycloset

Generic Name
Bromocriptine

Cycloset

Generic Name
Bromocriptine
Hyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate is indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Bromocriptine mesylate treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine mesylate therapy may be used to reduce the tumor mass prior to surgery. Acromegaly Bromocriptine mesylate therapy is indicated in the treatment of acromegaly. Bromocriptine mesylate therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate offers potential benefit before the effects of irradiation are manifested. Parkinson’s Disease Bromocriptine mesylate tablets are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson’s disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing “end of dose failure” on levodopa therapy. Bromocriptine mesylate therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (“on-off” phenomenon). Continued efficacy of bromocriptine mesylate therapy during treatment of more than 2 years has not been established. Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson’s disease with bromocriptine mesylate. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine mesylate-treated patients than in levodopa/carbidopa-treated patients. Patients unresponsive to levodopa are poor candidates for bromocriptine mesylate therapy.

Azilect

Generic Name
Rasagiline

Azilect

Generic Name
Rasagiline
AZILECT (rasagiline tablets) is indicated for the treatment of Parkinson’s disease (PD). AZILECT, a monoamine oxidase (MAO)-B inhibitor (MAOI), is indicated for the treatment of Parkinson’s disease ( 1 )
Showing 1-5 of 20
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances